{"id":765243,"date":"2023-06-21T16:23:00","date_gmt":"2023-06-21T20:23:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/"},"modified":"2023-06-21T16:23:00","modified_gmt":"2023-06-21T20:23:00","slug":"panbela-announces-closing-of-approximately-8-5-million-public-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/","title":{"rendered":"Panbela Announces Closing of Approximately $8.5 Million Public Offering"},"content":{"rendered":"
\n

\n MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) — Panbela\u00a0Therapeutics,\u00a0Inc.\u00a0<\/strong>(Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock (the \u201cPublic Warrants\u201d) at a purchase price of $3.75 per share and associated Public Warrants and $3.749 per pre-funded warrant and associated Public Warrants. The pre-funded warrants have an exercise price of $0.001 per share. The Public Warrants have an exercise price of $3.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance.<\/p>\n

Roth Capital Partners acted as sole placement agent of the offering.<\/p>\n

Gross proceeds, before deducting placement agent fees and commissions and offering expenses, were approximately $8.5 million. The Company intends to use the net proceeds from the proposed offering for the continued clinical development of its product candidates, working capital, business development and other general corporate purposes, which may include repayment of debt.<\/p>\n

The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-271729), as amended, that was declared effective by the U.S. Securities and Exchange Commission (\u201cSEC\u201d), on June 15, 2023.\u00a0 The offering was made solely by means of a prospectus. Copies of the accompanying prospectus relating to and describing the terms of the offering may be obtained at the SEC\u2019s website at www.sec.gov or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at rothecm@roth.com.<\/p>\n

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.<\/p>\n

\n About\u00a0Panbela<\/strong>
\n
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela\u2019s lead assets are Ivospemin (SBP-101) and Flynpovi. Further information can be found at\u00a0www.panbela.com\u00a0<\/strong><\/a>.\u00a0<\/strong>Panbela\u2019s common stock is listed on The Nasdaq Stock Market LLC under the symbol \u201cPBLA\u201d.<\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statements<\/strong>
\n
\n This\u00a0<\/em>
\n press<\/em>
\n \u00a0release contains \u201cforward-looking statements,\u201d including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such\u00a0as:\u00a0\u201canticipate,\u201d\u00a0\u201cbelieve,\u201d \u201ccan,\u201d \u201cdesign,\u201d \u201cexpect,\u201d \u201cfocus,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d\u00a0\u201cpositioned,\u201d \u201cpotential,\u201d and \u201cwill.\u201d All statements other than statements of historical fact are statements that should be deemed forward-looking statements.\u00a0Forward-looking statements are neither historical facts nor assurances of future performance.\u00a0Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business,\u00a0<\/em>
\n future plans<\/em>
\n \u00a0and strategies, projections, anticipated events and trends, the economy\u00a0and other future conditions. Because forward-looking statements\u00a0relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and\u00a0many\u00a0of which are outside of our control.\u00a0Our actual results and financial condition may differ materially and adversely from the forward-looking statements.\u00a0Therefore, you should not rely on any of these forward-looking statements.\u00a0Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:\u00a0(i) our ability to obtain additional funding to execute our business and clinical development plans; (ii) progress and success of our clinical development program; (iii) the impact of the current COVID-19 pandemic on our ability to conduct our clinical trials; (iv) our ability to demonstrate the safety and effectiveness of our product candidates:\u00a0<\/em>
\n ivospemin<\/em>
\n \u00a0(SBP-101)\u00a0and eflornithine\u00a0(CPP-1X);\u00a0(v) our reliance on a third party for the execution of the registration trial for our product candidate\u00a0<\/em>
\n Flynpovi<\/em>
\n \u00a0; (vi) our ability to obtain regulatory approvals for our product candidates,\u00a0SBP-101 and\u00a0CPP-1X\u00a0in the United States, the European Union or other international markets; (vii) the market acceptance and level of future sales of our product candidates, SBP-101 and\u00a0CPP-1X; (viii) the cost and delays in product development that may result from changes in regulatory oversight applicable to our product candidates, SBP-101 and\u00a0CPP-1X; (ix) the rate of progress in establishing reimbursement arrangements with third-party payors; (x) the effect of competing technological and market developments; (xi) the costs involved in filing and\u00a0prosecuting patent applications and enforcing or defending patent claims;\u00a0(xii) our ability to maintain the listing of our common stock on a\u00a0national securities exchange;\u00a0and (xiii) such other factors as discussed in Part I, Item 1A under the caption \u201cRisk Factors\u201d in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on\u00a0Form 8-K. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it\u00a0<\/em>
\n is<\/em>
\n \u00a0made.\u00a0We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ\u00a0from those anticipated in any such forward-looking <\/em>
\n statement,\u00a0whether written or oral, whether\u00a0<\/em>
\n as\u00a0a result of<\/em>
\n \u00a0new information, future developments or otherwise.<\/em>\n <\/p>\n

Contact Information:<\/p>\n

Investors:
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com<\/p>\n

Media:
Tammy Groene
Panbela Therapeutics, Inc.
(952) 479-1196
IR@panbela.com<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) — Panbela\u00a0Therapeutics,\u00a0Inc.\u00a0(Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock (the \u201cPublic Warrants\u201d) at a purchase price of $3.75 per share and associated Public Warrants and $3.749 per pre-funded warrant and associated Public Warrants. The pre-funded warrants have an exercise price of $0.001 per share. The Public Warrants have an exercise price of $3.75 per share, are exercisable upon issuance, and … <\/p>\n

Continue reading “Panbela Announces Closing of Approximately $8.5 Million Public Offering”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765243","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPanbela Announces Closing of Approximately $8.5 Million Public Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Panbela Announces Closing of Approximately $8.5 Million Public Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) — Panbela\u00a0Therapeutics,\u00a0Inc.\u00a0(Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock (the \u201cPublic Warrants\u201d) at a purchase price of $3.75 per share and associated Public Warrants and $3.749 per pre-funded warrant and associated Public Warrants. The pre-funded warrants have an exercise price of $0.001 per share. The Public Warrants have an exercise price of $3.75 per share, are exercisable upon issuance, and … Continue reading "Panbela Announces Closing of Approximately $8.5 Million Public Offering"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-21T20:23:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Panbela Announces Closing of Approximately $8.5 Million Public Offering\",\"datePublished\":\"2023-06-21T20:23:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/\"},\"wordCount\":950,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/\",\"name\":\"Panbela Announces Closing of Approximately $8.5 Million Public Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk=\",\"datePublished\":\"2023-06-21T20:23:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/panbela-announces-closing-of-approximately-8-5-million-public-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Panbela Announces Closing of Approximately $8.5 Million Public Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Panbela Announces Closing of Approximately $8.5 Million Public Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"Panbela Announces Closing of Approximately $8.5 Million Public Offering - Market Newsdesk","og_description":"MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) — Panbela\u00a0Therapeutics,\u00a0Inc.\u00a0(Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock (the \u201cPublic Warrants\u201d) at a purchase price of $3.75 per share and associated Public Warrants and $3.749 per pre-funded warrant and associated Public Warrants. The pre-funded warrants have an exercise price of $0.001 per share. The Public Warrants have an exercise price of $3.75 per share, are exercisable upon issuance, and … Continue reading \"Panbela Announces Closing of Approximately $8.5 Million Public Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-21T20:23:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Panbela Announces Closing of Approximately $8.5 Million Public Offering","datePublished":"2023-06-21T20:23:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/"},"wordCount":950,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/","name":"Panbela Announces Closing of Approximately $8.5 Million Public Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk=","datePublished":"2023-06-21T20:23:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjM1MSM1NjU4ODczIzIwMjgxMTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/panbela-announces-closing-of-approximately-8-5-million-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Panbela Announces Closing of Approximately $8.5 Million Public Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765243"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765243\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}